Phase 1 Study Of Anitocabtagene Autoleucel For The Treatment Of Patients With Relapsed And/Or Refractory Multiple Myeloma: Results From At Least 1-year Follow-up In All Patients

被引：0

作者：

Frigault, Matthew ^{[1
]}

Rosenblatt, Jacalyn ^{[2
]}

Dhakal, Binod ^{[3
]}

Raje, Noopur ^{[1
]}

Cook, Danielle ^{[4
]}

Gaballa, Mahmoud ^{[5
]}

Emmanuel-Alejandro, Estelle ^{[2
]}

Nissen, Danielle ^{[6
]}

Banerjee, Kamalika ^{[7
]}

Rotte, Anand ^{[7
]}

Heery, Christopher ^{[7
]}

Avigan, David ^{[2
]}

Jakubowiak, Andrzej ^{[8
]}

Bishop, Michael ^{[8
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[3] Med Coll Wisconsin, Dept Med, BMT & Cellular Therapy Program, Milwaukee, WI 53226 USA

[4] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[7] Arcellx Inc, Redwood City, CA USA

[8] Univ Chicago, Chicago, IL 60637 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA-30

引用

页码：S19 / S20

页数：2

共 50 条

[1] Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in all Patients
Frigault, Matthew
Rosenblatt, Jacalyn
Dhakal, Binod
Raje, Noopur
Cook, Daniella
Gaballa, Mahmoud
Emmanuel-Alejandro, Estelle
Nissen, Danielle
Banerjee, Kamalika
Rotte, Anand
Heery, Christopher
Avigan, David
Jakubowiak, Andrzej
Bishop, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S553 - S553
[2] Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients
Frigault, Matthew J.
Rosenblatt, Jacalyn
Dhakal, Binod
Raje, Noopur S.
Cook, Daniella
Gaballa, Mahmoud
Emmanuel-Alejandro, Estelle
Nissen, Danielle
Banerjee, Kamalika C.
Rotte, Anand
Heery, Christopher R.
Avigan, David
Jakubowiak, Andrzej J.
Bishop, Michael R.
BLOOD, 2023, 142
[3] Three- Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma
Fu, Chengcheng
Chen, Wenming
Cai, Zhen
Yan, Lingzhi
Wang, Huijuan
Shang, Jingjing
Wu, Yin
Yan, Shuang
Gao, Wen
Shi, Xiaolan
Han, Xiaoyan
Tang, Fang
Zheng, Gaofeng
Wen, Yanling
Meng, Xingxing
Zheng, Wei
Wang, Huamao
Li, Zonghai
BLOOD, 2023, 142
[4] Updated long-term follow-up results of a phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with equecabtagene autoleucel
Li, Chunrui
Wang, Di
Fang, Baijun
Huang, He
Li, Jianyong
Chen, Bing
Liu, Jing
Ren, Hanyun
Dong, Yujun
Hu, Kai
Liu, Peng
Zhang, Xi
Mi, Jian-Qing
Li, Zhenyu
Ding, Kaiyang
Cai, Song-Bai
Gui, Hong-Yu
Wang, Wen
Qiu, Lugui
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S196 - S197
[5] Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open- Label Study, at the ∼3 Year Follow-up
de Oca, Rocio Montes
Gu, Junchen
Zhao, Hao
Zelinsky, Kathy
Wu, Dianna
Davis, Cuc
Patel, Jaymala
Foulk, Brad
Boominathan, Rengasamy
Lau, Onsay
Smirnov, Denis
Lin, Yi
Jagannath, Sundar
Cohen, Adam D.
Haddish-Berhane, Nahor
Xu, Jean
Madduri, Deepu
Stevens, An-Sofie
Jackson, Carolyn Chang
Schecter, Jordan M.
Banerjee, Arnob
Geng, Dong
Zhu, Jieqing
Xu, Sifan
Zudaire, Enrique
BLOOD, 2023, 142
[6] Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
Richardson, Paul G.
Chanan-Khan, Asher A.
Lonial, Sagar
Krishnan, Amrita Y.
Carroll, Michael P.
Alsina, Melissa
Albitar, Maher
Berman, David
Messina, Marianne
Anderson, Kenneth C.
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (06) : 729 - 740
[7] Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up
James R. Berenson
Hank H. Yang
Robert A. Vescio
Youram Nassir
Russell Mapes
Shi-pyng Lee
Joanna Wilson
Ori Yellin
Blake Morrison
Jacqueline Hilger
Regina Swift
Annals of Hematology, 2008, 87
[8] Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up
Berenson, James R.
Yang, Hank H.
Vescio, Robert A.
Nassir, Youram
Mapes, Russell
Lee, Shi-pyng
Wilson, Joanna
Yellin, Ori
Morrison, Blake
Hilger, Jacqueline
Swift, Regina
ANNALS OF HEMATOLOGY, 2008, 87 (08) : 623 - 631
[9] Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
Popat, Rakesh
Nooka, Ajay
van de donk, Niels
Moreau, Philippe
Bhutani, Manisha
Oriol, Albert
Martin, Thomas
Rosinol, Laura
Mateos Manteca, Maria-Victoria
Bahlis, Nizar J.
Garfall, Alfred
Besemer, Britta
Martinez-Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Huang, Lin
Vishwamitra, Deeksha
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S80 - S80
[10] Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma
Garfall, Alfred L.
Nooka, Ajay K.
van de Donk, Niels W. C. J.
Moreau, Philippe
Bhutani, Manisha
Oriol, Albert
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martinez-Lopez, Joaquin
Krishnan, Amrita Y.
Delforge, Michel
Huang, Lin
Vishwamitra, Deeksha
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →